Odyssey Therapeutics, Inc. IPO - What You Need to Know

Thinking about the Odyssey Therapeutics IPO? Biotech can feel like a black box if you aren't a scientist. Here is a plain-English breakdown of what you are looking at.

1. What does this company do?

Odyssey is a "drug discovery engine." They focus on creating precision medicines for cancer and inflammatory diseases. Instead of just treating symptoms, they use a special platform to target proteins that were previously considered "undruggable." Their lead programs include:

• OD-001: A drug currently in early-stage testing for inflammatory diseases.
• OD-002: A drug currently in early-stage testing for autoimmune and inflammatory conditions.

Think of them as a high-tech lab using machine learning and biology to build the next generation of "smart" medicines.

2. How do they make money?

Right now, Odyssey makes no money. They have no products for sale and are burning through cash to fund research. In 2025, they lost $148.6 million. Since starting in 2021, they have lost $568.1 million in total.

The company warns there is "substantial doubt" about their ability to stay in business. Simply put, they spend money much faster than they earn it. They need this IPO to survive. If they cannot raise enough cash, or if their research fails, they may run out of money entirely.

3. What will they do with the IPO money?

Odyssey plans to use the cash from this IPO to fund their research through the second half of 2028. They will use the funds to:

• Move OD-001 and OD-002 through clinical trials.
• Develop new drug candidates.
• Hire more scientists and expand their labs.
• Pay for patents to protect their inventions.

4. What are the main risks?

Biotech is high-risk. Here is the reality:

• The "Going Concern" Warning: The company may not have enough cash to survive without constant new funding.
• Dilution: To keep the lights on, they will likely sell more shares later. This means more shares are issued, reducing your ownership percentage of the company.
• The "All or Nothing" Risk: They have no products on the market. If their lead drugs fail in trials or do not get FDA approval, the company has no other way to make money. This could lead to a total loss of your investment.
• Key Person Risk: The company relies heavily on its founder, Dr. Gary Glick. He also leads another firm, Charm Therapeutics. This split focus could hurt Odyssey’s progress.

5. Who is running the company?

Dr. Gary Glick leads the company. He is a serial entrepreneur who previously founded firms like Scorpion Therapeutics. While he has a strong track record, remember that he is balancing his time between Odyssey and Charm Therapeutics.

6. Where will it trade?

• Exchange: Nasdaq
• Ticker Symbol: ODTX

A final piece of advice: Investing in a company with no revenue is a bet on the science. Given the warning about their survival, this is an extremely speculative investment. Before you buy, ask yourself if you are comfortable with the possibility that the company may never bring a product to market. Only use money you can afford to lose.

Disclaimer: I am an AI, not a financial advisor. IPOs are volatile. Always read the official S-1 filing before investing.